Costs of conservative treatment of patients with cholangitis and cholesystitis/Troskovi konzervativnog lecenja pacijenata sa holangitisom i holecistitisom

Citation metadata

Authors: Sandra Stefan Mikic, Sinisa Sevic, Vedrana Petric, Tomislav Preveden, Jelena Kalember and Danijela Stankovic Baricak
Date: Dec. 2014
From: Medicinski Pregled(Vol. 67, Issue S2)
Publisher: Drustvo Lekara Vojvodine
Document Type: Report
Length: 3,846 words

Main content

Abstract :

Introduction. There are no guidelines for treating bacterial infections in our country. Antibacterial drugs are selected empirically, which is not always in accordance with the recommended therapy coming from the countries that have their own pharmacotherapy protocols. This study reviews the differences between the standard conservative treatment of cholangitis/cholecystitis and treatment implemented in accordance with current pharmacotherapy guidelines of other countries. The assessment of the therapeutic efficacy of antibacterial drugs implemented in the treatment of cholangitis/ cholecystitis and economic viability of that implementation was one of the aims of this study, and another one was comparison of the efficiency and cost of medical treatment using physician's therapy of choice and treatment according to pharmacotherapy guidelines. Material and Methods. The study was carried out over a threeyear period at the Department of Infectious Diseases of the Clinical Center of Vojvodina. It included 72 patients with the diagnosis of cholangitis/cholecystitis who were divided into two groups. The control group was treated according to the physician's therapy of choice, while the test group was treated in accordance with pharmacotherapy guidelines. The efficiency and cost of medical treatment were determined for both groups. Results. The comparison of the efficiency and costs of medical treatment of cholangitis/cholecystitis before and after introducing pharmacotherapy guidelines showed no significant differences in the efficiency of administered therapies. However, the cost of medical treatment carried out in accordance with pharmacotherapy guidelines showed a decrease of 17.24%. Conclusion. Medical treatment using physician's antibacterial therapy of choice and the one which is in accordance with pharmacotherapy guidelines for treating cholangitis/cholecystitis show no differences in terms of efficiency. However, medical treatment proved to be more affordable in the group of patients treated in accordance with pharmacotherapy guidelines of other countries. Key words: Cholangitis; Cholecystitis; Anti-Bacterial Agents; Drug Costs; Physician's Practice Patterns; Guidelines as Topic; Treatment Outcome Uvod. U Srbiji ne postoje smernice za lecenje bakterijskih infekcija. Antibakterijski lekovi se biraju prema licnom izboru lekara, sto nije uvek u skladu sa preporucenom terapijom u zemljama koje imaju svoje farmakoterapijske protokole. Ovim istrazivanjem su sagledane razlike u uobicajenoj terapiji konzervativnog lecenja holangitisa/holecistitisa i terapiji sprovedenoj prema aktuelnim fermakoterapijskim smernicama iz drugih zemalja. Procenjena je terapijska efikasnost antibakterijskih lekova primenjenih u terapiji holangitisa/holecistitisa i ekonomska opravdanost ove primene. Poredena je efikasnost i cena lecenja prema licnom izboru lekara i prema farmakoterapijskim smernicama. Materijai i metode. Istrazivanje je sprovedeno na Klinici za infektivne bolesti Klinickog centra Vojvodine u periodu od 3 godine. Obuhvacena su 72 bolesnika sa dijagnozom holangitis/ holecistitis, koji su bili podeljeni u dve grupe. Kontrolna grupa bolesnika je dobijala terapiju prema licnom izboru lekara, dok je ispitivana grupa dobijala terapiju prema farmakoterapijskim smernicama. Ustanovljana je efikasnost i cena lecenja kod obe grupe. Rezultati. Na osnovu poredenja efikasnosti i cene lecenja holangitisa/holecistitisa pre i nakon uvodenja farmakoterapijskih smernica, ustanovljeno je da nema znacajne razlike u efikasnosti primenjenih terapija, dok je cena lecenja u grupi pacijenata nakon primenjenih smernica pokazala ustedu materijalnih troskova od 17,24%. Zakljucak. Efikasnost lecenja holangitisa/holecistitisa antibiotskom terapijom prema licnom izboru lekara i lecenja prema farmakoterapijskim smernicama je jednaka. Lecenje je bilo materijalno povoljnije u grupi bolesnika lecenih prema aktuelnim farmakoterapijskim smernicama iz drugih zemalja. Kljucne reci: Holangitis; Holecistitis; Antibiotici; Troskovi lecenja; Lekarska empirijska praksa; Vodici; Ishod lecenja

Source Citation

Source Citation
Mikic, Sandra Stefan, et al. "Costs of conservative treatment of patients with cholangitis and cholesystitis/Troskovi konzervativnog lecenja pacijenata sa holangitisom i holecistitisom." Medicinski Pregled, vol. 67, no. S2, Dec. 2014, pp. SS44+. Accessed 28 Jan. 2022.
  

Gale Document Number: GALE|A403449606